JPRN-UMIN000027190Completed未知
The effect of the combination treatment with tiotropium and olodaterol compared to tiotropium on symptoms, respiratory functions and physical activity in maintenance naive Japanese patient with COPD - The effect of the combination treatment with tiotropium and olodaterol compared to tiotropium on symptoms, respiratory functions and physical activity in maintenance naive Japanese patient with COPD
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Saga University
- Enrollment
- 80
Study Overview
Brief Summary
Tiotropium/olodaterol treatment reduced the duration of physical activity with 1.0-1.5METs(regression coefficient,-43.6 [95%CI -84.1, -3.1], p=0.04)in a multiple regression model adjusted for cofounding factors such as age, FEV1, total CAT scores, 6MWD, and TDI.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 40years-old to 85years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.Patients who have bronchial asthma 2.Patients who are able to examine a pulmonary function test 3.Patients who are disturbed in walk ability or have a bone fracture 4.Patients who have experiences of exacerbation of COPD within 1 month 5.Patients with paroxysmal tachycardia (over 100 / min) and life threatening arrhythmia 6.Patients who have experiences of acute myocardial infarction or heart failure within 1 year 7.Patients who have experiences of malignant tumor ( excluding basal cell carcinoma or epithelial cancer of skin) within 5 years 8.Patients who do not understand purpose or method of the study 9.Patients with dementia 10.Patients who are being treated for depression and neurosis 11.Patients who have angle-closure glaucoma, benign prostatic hyperplasia with dysuria and hypersensitivity to atropine and its analogous substances or components of the drug 12.Patients who are judged not to be suitable as subjects
Investigators
Similar Trials
Completed
Phase 3
Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02172300Boehringer Ingelheim198
Completed
Phase 4
Cardiovascular Function in COPD PatientsPulmonary Disease, Chronic ObstructiveNCT03055988Boehringer Ingelheim76
Completed
Phase 4
Effects of Tiotropium on Walking Capacity in Patients With COPDChronic Obstructive Pulmonary DiseaseNCT01307189Laval University33
Completed
Phase 3
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.Pulmonary Disease, Chronic ObstructiveNCT02296138Boehringer Ingelheim7,903
Completed
Phase 4
Effect of Tiotropium + Olodaterol on Breathlessness in COPD PatientsPulmonary Disease, Chronic ObstructiveNCT02853123Boehringer Ingelheim106